The Filing Desk

Dianthus Therapeutics vs Oramed Pharmaceuticals

Dianthus Therapeutics DNTH · Oramed Pharmaceuticals ORMP · Pharmaceuticals

Dianthus Therapeutics reported revenue of $2 million in fiscal 2025, about the same as Oramed Pharmaceuticals' $2 million in fiscal 2025. Dianthus Therapeutics had an operating margin of -8739.3%, against -754.4% at Oramed Pharmaceuticals. Free cash flow was −$129 million at Dianthus Therapeutics and −$9 million at Oramed Pharmaceuticals.

Side by side

Dianthus TherapeuticsOramed Pharmaceuticals
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$2M$2M
Revenue growth−67.3%—
Revenue growth a year, last 5 years—−5.8%
Gross margin—0.7%
Operating margin−8,739.3%−754.4%
Net margin−7,973.3%3,202.5%
Free cash flow−$129M−$9M
Free cash flow margin−6,349.4%−457.7%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$5M
Change in diluted share count15.9%3.8%
Last close$84.83$3.69
P/E at the last close—1.1×
Insider trades, last 12 monthssold $75.1 millionsold $941,874
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Dianthus TherapeuticsOramed Pharmaceuticals
Operating margin
Percent of revenue
Dianthus TherapeuticsOramed Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Dianthus TherapeuticsOramed Pharmaceuticals

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Dianthus Therapeutics and Oramed Pharmaceuticals pages.